Filing Flows › Integrated Biopharma (INBP) › Q4 FY26 › vs Q3 FY26
Integrated Biopharma (INBP) Q4 FY26 vs Q3 FY26 (quarter over quarter)
Integrated Biopharma's revenue fell $311K (-3%) from $10.1M in Q3 FY26 to $9.8M in Q4 FY26. The biggest changes: Contract Manufacturing −$345K (-4%); Other Nutraceutical Business +$34K (+12%).
Integrated Biopharma, Q4 FY26: revenue $9.8M (-31% year over year), operating margin -8.9%, net loss $1.4M, operating cash flow −$1.2M. The chart draws each line against Q3 FY26, the increases inside each band.
Every line
| Line | Q4 FY26 | Q3 FY26 | Change | % |
|---|---|---|---|---|
| Contract Manufacturing | $9.5M | $9.8M | −$345K | -4% |
| Other Nutraceutical Business | $318K | $284K | $34K | +12% |
| Revenue | $9.8M | $10.1M | −$311K | -3% |
| Net loss | $1.4M | $837K | $529K | +63% |
| Costs & expenses | $11.2M | $11.2M | −$11K | -0.1% |
| Operating costs | $10.7M | $11.2M | −$527K | -5% |
| Income tax | $516K | −$198K | $714K | — |
| Cost of revenue | $9.8M | $10.4M | −$615K | -6% |
| Operating cash sources | $1.4M | $837K | $529K | +63% |
| Depreciation | $70K | $68K | $2K | +3% |
| Share-based compensation | $51K | $50K | $1K | +2% |
| Working capital & other | $51K | $1.2M | −$1.2M | -96% |
| Cash used in operations | $1.2M | −$517K | $1.7M | — |
| Net loss absorbed | $1.4M | $837K | $529K | +63% |
Questions
How much did Integrated Biopharma's revenue grow quarter over quarter in Q4 FY26?
Integrated Biopharma's revenue fell $311K (-3%) from $10.1M in Q3 FY26 to $9.8M in Q4 FY26.
What drove Integrated Biopharma's revenue change in Q4 FY26?
Contract Manufacturing −$345K (-4%); Other Nutraceutical Business +$34K (+12%).